Aadi Bioscience (NASDAQ:AADI) Trading Down 1.7% – Time to Sell?

Shares of Aadi Bioscience, Inc. (NASDAQ:AADI) dropped 1.7% during mid-day trading on Thursday . The stock traded as low as $4.04 and last traded at $4.07. Approximately 599,377 shares changed hands during trading, an increase of 130% from the average daily volume of 261,100 shares. The stock had previously closed at $4.14.

Aadi Bioscience Price Performance

The firm has a market cap of $100.52 million, a PE ratio of -1.79 and a beta of 0.68. The business has a 50-day moving average price of $4.11 and a two-hundred day moving average price of $3.75.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for genomically defined cancers. Headquartered in Redwood City, California, Aadi Bioscience was founded in 2012 and went public in 2019 on the Nasdaq Stock Market under the ticker AADI. The company’s research strategy centers on identifying molecular drivers of tumor growth and designing small-molecule inhibitors that target these pathways.

The company’s lead product candidate, fimepinostat (CUDC-907), is a novel dual inhibitor of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K).